<DOC>
	<DOC>NCT02381886</DOC>
	<brief_summary>A Phase I study of IDH305 in patients with advanced malignancies that harbor IDH1R132 mutations.</brief_summary>
	<brief_title>A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Documented IDH1R132mutant tumors ECOG performance status â‰¤ 2 Patients who have received prior treatment with a mutantspecific IDH1 inhibitor (with the exception of glioma patients) Medical conditions that would prevent the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures such as the presence of other clinically significant cardiac, respiratory, gastrointestinal, renal, hepatic or neurological disease. Acute Promyelocytic Leukemia Women who are pregnant or lactating Other protocoldefined Inclusion/Exclusion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>IDHR132 mutations</keyword>
	<keyword>IDH305</keyword>
	<keyword>IDH</keyword>
	<keyword>IDH1</keyword>
	<keyword>AML</keyword>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Myeloid</keyword>
	<keyword>Acute</keyword>
	<keyword>MDS</keyword>
	<keyword>Myelodysplastic Syndrome</keyword>
	<keyword>Glioma</keyword>
	<keyword>Oligodendroglioma</keyword>
	<keyword>Astrocytoma</keyword>
	<keyword>Glioblastoma</keyword>
	<keyword>Cholangiocarcinoma</keyword>
	<keyword>Solid Tumors</keyword>
</DOC>